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Background: The role of relative telomere length (RTL) as a marker of cardiovascular 
prognosis and quality control of the disease course remains to be found out. The aim of the study 
was to determine the relationship between the relative blood leukocyte telomere length (RLTL), 
relative buccal epithelium cell telomere length (RBTL) and achieving blood pressure targets 
(BPTs) in hypertensive (H) individuals with type 2 diabetes mellitus (T2DM) and without 
T2DM. Material and methods: In 156 patients with stage II hypertension (96 of them had 
T2DM), carbohydrate metabolism parameters and blood pressure levels were evaluated. RLTL 
and RBTL were determined by a real time quantitative PCR. 
Results: A combination of hypertension and T2DM was associated with significantly greater 
RLTL (р = 0.009) and RBTL (р = 0.001) compared with isolated hypertension. There was no 
convincing evidence of BPT influence on the change in the RLTL in isolated hypertension. 
Achieving BP targets was associated with a paradoxical shortening of RBTL. There was a 
significant shortening of RTL in hypertensive patients with T2DM when the BPTs were not 
reached. An analysis of variance revealed a significant influence of BPTs on the RBTL and 
RLTL. 
Conclusion: Patients with a comorbid course of hypertension and T2DM had more pronounced 
decrease in the RTL. Target levels of blood pressure have a more significant effect on the RLT 
than the glycemic control in patients with concomitant T2DM. An additional determination of 
the RBTL enhances the diagnostic and prognostic power when evaluating the effectiveness of 
correcting cardiovascular risk factors including blood pressure. 




Telomeres are gene sequences present at chromosomal ends and are responsible for 
maintaining genome integrity. Telomere length decreases progressively with advancing age and 
thus is considered as a biomarker of chronological aging. This age-associated decrease in the 
length of telomere is linked to various age-associated diseases like diabetes, hypertension, 
Alzheimer's disease etc. [1]. There are studies which support that telomere length is associated 
with a number of chronic conditions including dyslipidemia, hypertension, atherosclerosis, and 
poor cardiovascular disease prognosis [2, 3]. Furthermore, a number of studies indicate that 
telomere attrition is positively correlated with diabetes and diabetic complications [4, 5].  
A number of studies on various samples show that the average telomere length of 
circulating leukocytes is shorter in hypertensive than in normotensive subjects [6]. The study 
shows that moreover, telomere length represents an independent risk factor for the development 
of coronary artery disease both in patients with hypertension and in subjects with normal blood 
pressure (BP) [6]. Modern studies of telomere length dynamics also show that aging and age-
related diseases, in addition to synergistic effects, affect telomere length independently of one 
another.  
Impact on modified risk factors, one the most significant among them being considered 
BP levels, is one of the strategic tasks of treating patients with the established diagnosis of 
cardiovascular disease, including arterial hypertension. Although classic risk factors have been 
found to predict the occurrence of hypertension, there is wide variation in disease manifestation 
in individuals who have the same risk profile. It is believed that telomere length can be 
considered as a marker of cardiovascular aging [7], but its role in cardiovascular prognosis and 
quality control of the disease course remains to be clarified. 
Blood is commonly used to study telomere lengths, since peripheral blood leukocytes are 
an excellent object for studying the dynamics of telomeres. Many authors believe that the 
method for determining the telomere length in the peripheral blood can provide reliable data for 
determining the relative length of telomeres in other tissues [8] and shortening of telomeres in 
peripheral blood leukocytes can serve not only as a marker of aging, but also as an indicator of 
the systemic pathological stress. In recent years, more and more scientific papers have appeared, 
in which much attention is paid to the use of buccal epithelium as an alternative source of 
biological material for telomeric test due to the non-invasive procedure of material sampling [9, 
10]. Nowadays, there is insufficient data on the length of telomeres, including that in the buccal 
epithelium, in the presence of the combined age-associated pathology, on the influence of 
various risk factors, primarily modifiable, on the relative length of telomeres, including that of 
the Ukrainian population. Data on the comparative characteristics of the relative telomere length 
(RTL) in the blood leukocytes and buccal epithelial cells in combined course of arterial 
hypertension and type 2 diabetes mellitus (T2DM), as the most frequently encountered combined 
pathologies among older age groups, and the effect of different levels of BP control on telomere 
length in this category of patients has not been found.  
The aim of the study was to determine the impact of achieving BP targets on the relative 
telomere length of blood leukocytes and buccal epithelium in individuals suffering from 
hypertension, both in combination with T2DM and without T2DM. 
 
Materials and methods 
The study included 156 patients (62 men and 94 women, the average age — 62.66 ± 4.21 
years), with hypertension stage II (disease duration of 10.2 ± 3.7 years); 96 of them had T2DM 
(disease duration of 4.1 ± 2.4 years). All patients were divided in two groups: group 1 – 60 
patients with isolated hypertension (n = 60) and group 2 — patients with hypertension and 
T2DM. The control group consisted of 22 volunteers — age- and gender-matched and without 
cardiovascular or endocrine diseases. For the patients’ selection, the hypertension diagnostic 
criteria, in accordance with the ESC/ERS Guidelines (2013), were applied [11]. The diagnosis of 
T2DM has been established in compliance with the international recommendations of the 
American Diabetes Association and the European Association for the Study of Diabetes [12]. 
Against the background of dietary recommendations, all patients received basic therapy 
in accordance with international and national guidelines for the management of patients with the 
relevant pathology [11, 12]. Therefore, stable antihypertensive therapy was received by all 
patients for at least 6 months prior to inclusion into the study with individually-selected doses 
using angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ACEI/ARB), 
diuretics (indapamide); some patients received calcium antagonists (amlodipine or 
lercanidipine). As antidiabetic therapy, patients with T2DM received metformin in individually-
selected doses ranging from 1000 to 2000 mg per day, and 3 patients (3.13%) additionally 
received a sodium glucose linked transporter-2 inhibitor (SGLT2) and 5 patients (5.21%) — an 
agonist of glucagon-like peptide 1 (GLP 1). The study did not include patients with diabetes 
mellitus type 1 (and other endocrinological disorders), symptomatic hypertension, clinical signs 
of coronary heart disease or severe concomitant chronic diseases. 
BP was recorded as the arithmetic mean, three measurements being carried out with the 
2-minutes intervals in a sedentary position on the dominant hand.  
Laboratory tests included the determination of fasting glucose concentration and 
glycosylated hemoglobin (HbA1c) levels by standard conventional techniques.  
Telomere length was measured on a CFX96 touch real-time polymerase chain reaction 
detection system (Bio-Rad Laboratories) in DNA isolated from blood leukocytes and buccal 
epithelium using the DNA-sorb blood kit (Amplisens, RF). We used a modified monochrome 
multiplex quantitative polymerase chain reaction (PCR) method [13], as described previously 
[14]. The telomere length was calculated using the ΔΔCt method [13]. 
Statistical data processing was carried out using the computer software IBM SPSS 
Statistics V. 21.0. To determine the nature of the data distribution, the Shapiro-Wilk criterion 
was used. When performing the statistical analysis, quantitative and qualitative variables were 
used. Qualitative data were presented as percentages; quantitative data — in the form of the 
mean and standard error (M ± m). Testing the significance of differences between the two groups 
was carried out using the Student's t-test. The frequency of traits in the groups was compared 
using the Pearson χ2 test. The differences were statistically significant at p < 0.05. When 
studying the influence of risk factors on the telomere relative length, single-factor analysis of 
variance was used. Testing the hypothesis of dispersion homogeneity was performed using the 
Levene’s test. 
The work was performed in compliance with the basic provisions of the World Medical 
Association (WMA) Declaration of Helsinki on ethical principles for medical research involving 
human subjects (1964–2000) and MOH of Ukraine Order No. 690 dated September 23, 2009. 
The study was approved by the Bioethics Commission at the Kharkiv National Medical 
University in accordance with the principles set forth in the Declaration of Helsinki. 
 
Results 
The levels of both systolic BP (SBP) and diastolic BP (DBP) in patients of groups 1 and 
2 reliably differed from those in the control group (Tab. I).  
The presence of comorbid pathology was accompanied by higher SBP and DBP levels 
than in isolated hypertension; however, significant differences were only observed for SBP (p = 
0.012). The presence of hypertension, regardless of concomitant T2DM, was accompanied by a 
significant shortening of the RTL compared with the control group. The presence of T2DM was 
accompanied by an even greater shortening of telomere length, reaching reliable differences both 
in RBTL (p = 0.001) and RLTL (p = 0.009).  
We assessed the impact of the achieved target BP according to ESC guidelines (2018) on 
the RTL [15]. Thus, despite the long-term antihypertensive therapy and permanent BP control, 
which was the criterion for inclusion in our study, the target SBP levels was not reach by 23 
(38.33%) patients in group 1 and by 57 (59.37%) patients in group 2. Thirty-five (58.33%) 
patients in group 1 and 77 (80.21%) patients in group 2 did not reach the target DBP level. The 
target levels of both SBP and DBP were not achieved by 35 (58.33%) patients in group 1 and by 
57 (59.38%) patients in group 2. There was no convincing evidence obtained in patients with 
isolated hypertension of the influence of reaching target BP levels (both SBP and DBP) on the 
change in the RLTL. Blood pressure targets were accompanied by a paradoxical shortening of 
RBTL (Tab. II). 
The presence of concomitant T2DM is accompanied by a significant shortening of the 
RTL when the target levels of both SBP and DBP are not reached, which is a significant fact 
confirming the importance of BP control in T2DM (RLTL when the target levels of SBP are 
reached — 1.15 ± 0.07,  and when the target levels of SBP are not reached — 0.86 ± 0.06, p 
<0.05; RBTL when the target levels of SBP are reached — 0.87 ± 0.03, and when the SBP target 
levels are not reached — 0.84 ± 0.08, p > 0.05; RLTL when the target levels of DBP are reached 
— 1.08 ± 0.04, and when the target levels of DBP are reached — 0.90 ± 0.07, p < 0.05; RBTL 
when reaching target DBP levels — 0.85 ± 0.04, if not reaching target DBP levels — 0.83 ± 
0.05, p > 0.05, respectively). Thus, there is a unidirectional tendency for shortening RLTL and 
RBTL when the target levels of SBP and DBP are not reached. 
When carrying out a similar analysis of carbohydrate metabolism among group 2 
patients: the RTL was assessed in the carbohydrate metabolism compensation and in its absence, 
no convincing data was obtained on the effect of glycemic control on the RTL (Tab. III).  
A longer RTL was observed in the buccal epithelium cells, while in the blood leukocytes, 
on the contrary, there was a shortening of the RTL at the levels of fasting glucose and 
glycosylated hemoglobin close to normal. In the subanalysis of the impact of achieving the target 
SBP and DBP, an increase in the RTL occurred, regardless of the level of glycemic control. 
To determine the effect of BP and carbohydrate indicators changing in two directions: 
reaching the target levels and not reaching them, on the RTL, the variance analysis was used 
according to the traditional scheme. Performing the variance analysis in group 1 revealed a 
significant effect of DBP (p = 0.046) on the distribution of the RBTL by quartiles. Also in group 
1, a reliably significant effect of reaching the target SBP levels on the presence of a longer RLTL 
(p = 0.001) was revealed. The dispersion analysis in group 2 revealed the presence of a reliably 
significant effect of the level of fasting glucose (p = 0.029) on the RBTL. The significant effect 
of the level of glycosylated hemoglobin (p = 0.034) on the distribution of the RBTL by quartiles 
in this group was revealed. 
 
Discussion 
The presence of significant differences in telomere length between the studied groups 
confirms the existing opinion about the more pronounced synergistic negative effect of age-
associated comorbidity on the aging process than isolated pathology. The presence of shortened 
telomeres in hypertensive patients compared with controls in our study is quite consistent with 
the data of other authors [2, 6]. The absence of a significant effect of achieving target BP levels 
on changes in the RTL in patients with isolated hypertension can be explained by the fact that 
hypertensive subjects already experienced excessive telomere depletion at the early stages of the 
disease (the average duration of hypertension in our study was 10.2 ± 3.7 years), which makes an 
additional change in telomere length with relative BP control less obvious. However, this 
phenomenon requires further study. 
It is known that the achievement of target BP levels in T2DM is no less important for 
predicting the further course of the disease and the development of its complications than the 
achievement of the target level of glycemic control [16]. The presence of concomitant T2DM in 
group 2 in our study is accompanied by a significant shortening of the RTL when the target 
levels of both SBP and DBP are not reached, which is a significant fact confirming the 
importance of BP control in diabetes. The unidirectional tendency to shorten both RLTL and 
RBTL when target levels of BP are not reached can also serve as evidence of the special 
importance of BP control in the presence of concomitant T2DM. 
The absence of the significant effect of carbohydrate metabolism compensation in 
diabetes on the RTL in our study can possibly be explained by the absence of diabetic 
complications in our patients according to the study design, as well as metformin use, which has 
a beneficial effect not only on carbohydrate metabolism, but also reduces the manifestation of 
oxidative stress which can lead to inhibition of vascular aging progression [17, 18].  
All this indicates the necessity for a more detailed study of this issue, taking into account 
not only the achievement of target levels of studied factors but also the features of 
pharmacological and non-pharmacological methods of exposure. Our data are in support of 
higher plasticity of shortening and elongations of RTL, including under the influence of BP 
levels [19]. In addition, it is necessary to take into account TL interindividual variability.  
The study has several limitations. The inconsistency of our work data is also explained by 
the fact that we studied the length of telomeres in different tissue samples (leukocytes and buccal 
epithelium cells), which are subjected to various influences, including external ones. The sample 
size in this study does not allow for a more complete analysis, which would include an 
assessment of different patient habits, physical activity, individual variability of possible drug 
effects on telomere attrition, etc.  
 
Conclusions 
In patients with isolated hypertension and hypertension in combination with type 2 diabetes 
mellitus, the reduction in the relative telomere length compared to normotensive individuals was 
observed, and in patients with comorbid pathology, the changes were more pronounced. In case 
of isolated hypertension, the achievement of the blood level targets associated with a 
controversial effect on relative telomere length both in blood leukocytes and in the buccal 
epithelium. Achieving the target values of blood pressure has a more significant effect on the 
relative telomere length than the glycemic control in patients with combined course of 
hypertension and type 2 diabetes mellitus. Additional determining the relative telomere length in 
buccal epithelial cells in combination with determining the relative telomere length of blood 
leukocytes enhances the diagnostic and prognostic power of this parameter when assessing the 
efficacy of correcting cardiovascular risk factors such as blood pressure. 
The article is a fragment of the research project ‘Improving the diagnosis and treatment 
of comorbid pathology (arterial hypertension and type 2 diabetes mellitus) based on the 
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Table I. Comparative characteristics of carbohydrate indices, blood pressure levels and relative 
telomere length (M ± m)  
Index Group1  
(n = 60) 
Group 2  





Fasting blood glucose [mmol/L] 5.45 ± 0.12 8.90 ± 0.50 4.62 ± 1.08 р1–2 < 0.001 
HbA1c (%) 6.13 ± 0.11* 7.61 ± 0.19* 4.74+1.10 р1–2 < 0.001 
*р = 0.001 
SBP [mm Hg] 138.95 ± 2.83* 146.65 ± 
2.74* 
125.05+3.86 р1–2 = 0.012 
*р = 0.001 
DBP [mm Hg] 86.71 ± 1.62 90.05 ± 1.59* 78.19+7.01 *р < 0.001 
Relative blood leukocyte 
telomere length (RLTL), T/S  
1.27 ± 0.08 0.97 ± 0.08* 1.66 ± 0.52  р1–2 = 0.009 
*р = 0.005  
Relative buccal epithelium cell 
telomere length (RBTL), T/S  
1.26 ± 0.08* 0.90 ± 0.08* 2.33 ± 0.51  р1–2 = 0.001  
*р < 0.001 
HbA1c — glycosylated hemoglobin; SBP — systolic blood pressure; DBP — diastolic blood 
pressure; * — the difference is significant compared with the control group; р1–2 — the 
difference is significant between group 1 and group 2  
 
Table II. Comparative characteristics of relative telomere length in dependence of achieving 
blood pressure targets (M ± m) 
 Group1 
(n = 60) 
Group 2 
(n = 96) 








 ± 0.06 
1.20 
 ± 0.08 
1.17 





 ± 0.07 
0.86 
 ± 0.06* 
0.87 
 ± 0.03 
0.84 


















 ± 0.04 
0.83 





 ± 0.05 
 
1.21 
 ± 0.02 
 
1.15 







 ± 0.06 
 
0.88 
 ± 0.04* 
 
0.87 
 ± 0.03  
 
0.86 
 ± 0.06 
RLTL — relative blood leukocyte telomere length (T/S); RBTL — relative buccal epithelium 
cell telomere length (T/S); SBP — systolic blood pressure; DBP — diastolic blood pressure; * 
— the difference is significant compared with achieving target BP levels in appropriate subgroup 
and indicator 
 
Table III. Comparative characteristics of relative telomere length in dependence of achieving 
target levels of carbohydrate metabolism in patients with hypertension and type 2 diabetes 
mellitus (M ± m) 
Group 2 (n = 96) 
Index RLTL (T/S) RBTL (T/S) 
Presence of 
compensation 
Yes No Yes No 
Fasting glucose 
[mmol/L] 
0.83 ± 0.06 0.96 ± 0.03 0.95 ± 0.04 0.78 ± 
0.06* 
HbA1c (%) 0.82 ± 0.03 1.04 ± 0.05* 1.03 ± 0.03 0.60 ± 
0.04* 
RLTL — relative blood leukocyte telomere length (T/S); RBTL — relative buccal epithelium 
cell telomere length (T/S); * — the difference is significant (р < 0.05) compared with achieving 
target levels in appropriate subgroup and indicator 
